Effect of Efpeglenatide on Heart Failure Outcomes: A Participant-Level Exploratory Analysis of the Randomized AMPLITUDE-O Trial

What is it about?

GLP-1 receptor agonists have substantial reductions in major adverse cardiovascular events although their effect on heart failure outcomes is inconsistent. We found that patients with diabetes randomized to the GLP-1 RA efpeglenatide 4 or 6 mg weekly have significant reductions in hospitalization for heart failure alone and in combination with cardiovascular death compared to placebo.

Featured Image